Specific inhibitors targeting caspase-1/11 have been shown to effectively suppress protein expression, reduce neuroinflammatory markers, and improve survival rates, as demonstrated in studies involving acute pancreatitis, EAE, and non-canonical cell death. This evidence concerns the gene CASP1 and acute pancreatitis.